[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.232.62.209. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 847
Citations 0
Comment & Response
April 22, 2020

Initial Monthly Cost of Tafamidis—the Real Price for Patients

Author Affiliations
  • 1Brigham and Women’s Hospital Amyloidosis Program, Boston, Massachusetts
  • 2Nuclear Medicine Department, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3Partners Healthcare Specialty Pharmacy, Burlington, Massachusetts
  • 4Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA Cardiol. Published online April 22, 2020. doi:10.1001/jamacardio.2020.0863

To the Editor We concur entirely with the Viewpoint by Gurwitz and Maurer1 on the high price of tafamidis for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM). The authors briefly addressed the potential problem of access and affordability for patients but do not provide details on cost. As this is a disease of the elderly, most patients in the US receiving tafamidis are Medicare beneficiaries. Medicare has a multilayered structure for drug coverage, and patients may be subject to high copayments, which vary depending on several factors, including supplemental insurance. For those with a high copayment, pharmaceutical company–sponsored, income-based financial assistance may be available, and charitable foundations inconsistently have available funds, but both are on a year-to-year basis.

×